227
Participants
Start Date
July 29, 2019
Primary Completion Date
July 31, 2023
Study Completion Date
January 31, 2024
Lucitanib
Oral lucitanib will be administered once daily (QD) at the starting dose of 6 mg.
Lucitanib
Oral lucitanib will be administered once daily (QD). The dose will be 6 mg.
Lucitanib
"Oral lucitanib will be administered once daily (QD) at the starting dose of 6 mg.~Subjects will be allowed to intrapatient dose escalate in increments of 2 mg up to a total dose of 10 mg QD lucitanib if they meet the study specific clinical criteria."
Nivolumab
IV nivolumab 480 mg will be administered once every 4 weeks.
Saint Luc Univerisity Hospital, Brussels
University Hospitals Leuven, Campus Gasthuisberg, Leuven
Medical University of Innsbruck, Innsbruck
University Hospital Ghent, Ghent
NYU Langone Laura and Isaac Perlmutter Cancer Center, New York
Memorial Sloan Kettering Cancer Center, New York
University Hospital Reina Sofia, Córdoba
Magee-Womens Hospital of UPMC, Pittsburgh
Duke University School of Medicine, Durham
Navarra University Clinic, Madrid
La Paz University Hospital, Madrid
Florida Cancer Specialists, Sarasota
Tennessee Oncology, Nashville
Polyclinic S. Orsola-Malpighi, Bologna
Ohio State University Wexner Medical Center, Columbus
Kliniken Essen-Mitte, Essen
University Hospital Mannhein, Mannheim
Stephenson Cancer Center, Oklahoma City
Anschutz Cancer Pavilion, Aurora
"National Cancer Institute -IRCCS Fondazione G. Pascale", Naples
UCLA Jonsson Comprehensive Cancer Center, Los Angeles
UC San Diego Moores Cancer Center, San Diego
Swedish Cancer Institute, Seattle
Massachusetts General Hospital, Boston
University Hospital Carl Gustav Carus, Dresden
Foundation IRCCS Hospital Agostino Gemelli, Rome
University Hospital Vall d'Hebron, Barcelona
Lead Sponsor
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
European Network of Gynaecological Oncological Trial Groups (ENGOT)
OTHER
Clovis Oncology, Inc.
INDUSTRY